
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably due to its attractive current valuation, supported by net present value (NPV) analysis that indicates significant upside potential. The company’s lead therapeutic candidate, stenoparib, has demonstrated promising and durable clinical benefits, particularly in patients with advanced recurrent ovarian cancer, with recent data showing a median overall survival exceeding 25 months in its Phase 2 trial. This combination of robust clinical results and a favorable valuation strategy suggests a compelling growth opportunity for investors, balancing inherent risks with the promise of substantial returns.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an EPS of $(0.19), which fell short of expectations, indicating potential financial instability. The company continues to face significant risks associated with its product development, including potential failures in demonstrating safety and efficacy, regulatory approvals, and commercialization efforts, which could adversely affect its financial outlook. Additionally, ongoing balance sheet and liquidity concerns, coupled with broader market factors, further contribute to a negative perspective on the company's stock performance.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares